Utilisation and Safety of Polyethylene Glycol 3350 With Electrolytes in Children Under 2 Years: A Retrospective Cohort.

Author: AkricheFatma, AmlaniBharat, RoyDebabrata, ShakirSaad

Paper Details 
Original Abstract of the Article :
In the UK, Movicol paediatric plain (polyethylene glycol 3350 with electrolytes [PEG 3350+E], Norgine, UK), is licensed for chronic constipation in children 2 -11 years of age and faecal impaction (FI) from 5 years. This study aimed to investigate usage and characterise the risk profile in children ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549461/

データ提供:米国国立医学図書館(NLM)

Investigating the Safety and Usage of Polyethylene Glycol 3350 with Electrolytes in Young Children

Polyethylene glycol 3350 with electrolytes (PEG 3350+E) is a medication used to treat constipation, but its use in children under 2 years old is not fully understood. This research investigated the usage and safety profile of PEG 3350+E in this age group. Imagine a young camel learning to navigate the desert alongside its mother. Similarly, understanding the appropriate use of medications for young children is crucial for their safety and well-being.

PEG 3350+E is Used Off-Label for Constipation in Young Children

The study found that PEG 3350+E was frequently used off-label for constipation in children under 2 years old. This is like using a specific type of food for a young camel that was not originally intended for its diet. While this can be effective, it's important to carefully assess the risks and benefits of off-label use in young children.

Need for Further Research on PEG 3350+E in Young Children

This research highlights the need for further studies on the safety and efficacy of PEG 3350+E in children under 2 years old. Just as a young camel needs careful guidance to thrive in the desert, we need to ensure the safety and effectiveness of medications for our youngest patients. The study underscores the importance of continued research to understand the long-term effects of medications in this age group.

Dr.Camel's Conclusion

This study reminds us that children are particularly vulnerable to the side effects of medication. Just as a young camel needs extra care and attention, we must carefully assess the risks and benefits of medication for our youngest patients. The study highlights the importance of ongoing research to ensure the safe and effective use of medications in children.

Date :
  1. Date Completed 2021-07-09
  2. Date Revised 2022-12-19
Further Info :

Pubmed ID

33587408

DOI: Digital Object Identifier

PMC8549461

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.